Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma.
作者信息
Saifi Omran, Breen William G, Rule William G, Lin Yi, Munoz Javier, Kharfan-Dabaja Mohamed A, Peterson Jennifer L
机构信息
Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida.
Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
出版信息
JAMA Oncol. 2024 Jul 1;10(7):979-981. doi: 10.1001/jamaoncol.2024.1113.
Abstract
摘要
相似文献
1
Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma.针对有限的CART治疗前非霍奇金淋巴瘤的综合桥接放疗
JAMA Oncol. 2024 Jul 1;10(7):979-981. doi: 10.1001/jamaoncol.2024.1113.
2
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.将放射性物质与抗 CD19 嵌合抗原受体 T 细胞疗法联合用于复发/难治性非霍奇金淋巴瘤：多中心共识方法。
Am J Hematol. 2024 Jan;99(1):124-134. doi: 10.1002/ajh.27155. Epub 2023 Nov 11.
3
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?CAR T 细胞治疗后桥接放疗是否会影响非霍奇金淋巴瘤的失败模式？
Radiother Oncol. 2022 Jan;166:171-179. doi: 10.1016/j.radonc.2021.11.031. Epub 2021 Dec 7.
4
Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.嵌合抗原受体 T 细胞疗法治疗复发/难治性非霍奇金淋巴瘤患者中放射治疗的作用：当前研究和未来前景。
Crit Rev Oncol Hematol. 2024 Jul;199:104390. doi: 10.1016/j.critrevonc.2024.104390. Epub 2024 May 22.
5
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.不要本末倒置：放疗在 CAR-T 细胞治疗侵袭性 B 细胞非霍奇金淋巴瘤中的作用。
Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):999-1007. doi: 10.1016/j.ijrobp.2022.12.017. Epub 2022 Dec 21.
6
Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy.克隆性造血与嵌合抗原受体 T 细胞（CART）治疗患者的严重细胞因子释放综合征相关。
Transplant Cell Ther. 2024 Sep;30(9):927.e1-927.e9. doi: 10.1016/j.jtct.2024.06.008. Epub 2024 Jun 11.
7
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.嵌合抗原受体（CAR）T 细胞治疗后复发/难治性非霍奇金淋巴瘤采用挽救性放疗的早期经验。
Br J Haematol. 2020 Jul;190(1):45-51. doi: 10.1111/bjh.16541. Epub 2020 Mar 5.
8
Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.异基因造血干细胞移植和嵌合抗原受体（CAR）T 细胞治疗非霍奇金淋巴瘤。
Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10.
9
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.接受或不接受放疗桥接的复发/难治性 B 细胞 NHL 患者和局限性（<5 个部位）前 CART 疾病患者的结局。
Blood Adv. 2024 Sep 24;8(18):4877-4885. doi: 10.1182/bloodadvances.2024013647.
10
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.中枢神经系统桥接放疗在 CAR T 细胞治疗侵袭性 B 细胞淋巴瘤前实现快速细胞减灭。
Blood Adv. 2024 Oct 8;8(19):5192-5199. doi: 10.1182/bloodadvances.2024013393.
引用本文的文献
1
The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review.放疗在CAR-T治疗后复发或难治性弥漫性大B细胞淋巴瘤中的作用：一项系统文献综述
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251351065. doi: 10.1177/15330338251351065. Epub 2025 Jun 18.
2
Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study.嵌合抗原受体T细胞治疗前桥接放疗用于B细胞淋巴瘤：一项国际淋巴瘤研究组多中心研究
Blood Adv. 2025 Jul 8;9(13):3293-3303. doi: 10.1182/bloodadvances.2025015855.
3
Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.放射桥接疗法增强大B细胞淋巴瘤中CAR-T细胞疗效：一项单中心真实世界经验
Curr Oncol. 2025 Mar 17;32(3):173. doi: 10.3390/curroncol32030173.
4
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.侵袭性大B细胞淋巴瘤患者在嵌合抗原受体T细胞治疗前进行桥接放疗的疗效。
Front Immunol. 2025 Jan 31;16:1517348. doi: 10.3389/fimmu.2025.1517348. eCollection 2025.
5
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.桥接治疗后代谢肿瘤体积的反应决定了大 B 细胞淋巴瘤嵌合抗原受体 T 细胞治疗的结果。
Clin Cancer Res. 2024 Nov 15;30(22):5083-5093. doi: 10.1158/1078-0432.CCR-24-0830.
6
Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.符合桥接放疗条件的CAR T细胞治疗后有高失败风险的非霍奇金淋巴瘤患者的患病率。
Front Oncol. 2024 Aug 19;14:1425506. doi: 10.3389/fonc.2024.1425506. eCollection 2024.
7
Adaptive bridging radiation therapy for relapsed/refractory B-cell lymphoma patient undergoing CAR T-cell therapy: Case report.接受CAR T细胞治疗的复发/难治性B细胞淋巴瘤患者的适应性桥接放射治疗：病例报告
Clin Transl Radiat Oncol. 2024 Jul 30;48:100832. doi: 10.1016/j.ctro.2024.100832. eCollection 2024 Sep.
8
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma.接受CD19嵌合抗原受体T细胞（CAR-T）疗法治疗的大B细胞淋巴瘤患者的预后生物标志物。
Hemasphere. 2024 Aug 22;8(8):e130. doi: 10.1002/hem3.130. eCollection 2024 Aug.
9
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.接受或不接受放疗桥接的复发/难治性 B 细胞 NHL 患者和局限性（<5 个部位）前 CART 疾病患者的结局。
Blood Adv. 2024 Sep 24;8(18):4877-4885. doi: 10.1182/bloodadvances.2024013647.
Zotero 插件